Nilda Mesa Sells 255 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock

United Therapeutics Co. (NASDAQ:UTHR) Director Nilda Mesa sold 255 shares of the business’s stock in a transaction on Monday, December 30th. The shares were sold at an average price of $355.77, for a total transaction of $90,721.35. Following the completion of the transaction, the director now owns 5,528 shares of the company’s stock, valued at approximately $1,966,696.56. This represents a 4.41 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Nilda Mesa also recently made the following trade(s):

• On Friday, November 8th, Nilda Mesa sold 224 shares of United Therapeutics stock. The shares were sold at an average price of $412.28, for a total transaction of $92,350.72.

United Therapeutics Trading Up 2.1 %

Shares of UTHR opened at $360.22 on Friday. The firm has a 50-day moving average price of $370.27 and a 200 day moving average price of $349.97. United Therapeutics Co. has a 12-month low of $208.62 and a 12-month high of $417.82. The firm has a market capitalization of $16.08 billion, a P/E ratio of 15.82, a P/E/G ratio of 1.05 and a beta of 0.55.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.16 by $0.23. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The business had revenue of $748.90 million during the quarter, compared to the consensus estimate of $722.62 million. During the same quarter last year, the firm earned $5.38 EPS. The business’s revenue was up 22.9% compared to the same quarter last year. Equities research analysts predict that United Therapeutics Co. will post 25.22 earnings per share for the current fiscal year.

Institutional Investors Weigh In On United Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Renaissance Technologies LLC increased its position in shares of United Therapeutics by 1.1% during the 2nd quarter. Renaissance Technologies LLC now owns 2,174,692 shares of the biotechnology company’s stock worth $692,748,000 after purchasing an additional 22,978 shares during the last quarter. Geode Capital Management LLC increased its position in shares of United Therapeutics by 4.3% during the third quarter. Geode Capital Management LLC now owns 1,094,015 shares of the biotechnology company’s stock valued at $391,459,000 after acquiring an additional 45,566 shares during the last quarter. FMR LLC raised its stake in shares of United Therapeutics by 41.1% in the 3rd quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company’s stock valued at $386,168,000 after acquiring an additional 314,004 shares during the period. LSV Asset Management raised its stake in shares of United Therapeutics by 82.5% in the 2nd quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company’s stock valued at $307,837,000 after acquiring an additional 436,851 shares during the period. Finally, Dimensional Fund Advisors LP boosted its position in shares of United Therapeutics by 4.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 585,969 shares of the biotechnology company’s stock worth $186,656,000 after purchasing an additional 22,683 shares during the period. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on UTHR shares. Oppenheimer raised their target price on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. The Goldman Sachs Group boosted their price target on shares of United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a report on Friday, November 1st. TD Cowen increased their target price on United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a report on Monday, October 21st. LADENBURG THALM/SH SH lifted their price target on United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Finally, StockNews.com raised United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Monday. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $370.86.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.